Scientists have finally found out why MPA medroxyprogesterone, otherwise known as Provera performs just as well in low doses in small children who are dealing with early sex traits, as it does for women in high doses with breast cancer. You may have heard of Provera before as the drug that delivers hormone replacement therapy for women who are going through menopause.
Two scientists, named Lee and Auchus were trying to figure out why Provera is able to treat both early puberty as well as breast cancer. During the pre-teen years a chemical is released in the brain called gonadotropin-releasing hormone (GnRH). In a normal pre-teen body GnRH tells the ovaries and testes when to start making steroids. Low doses of Provera have shown to bind to the receptors in the brain and block GnRH production. There are certain diso
What Lee and Auchus found out was that Provera could inhibit certain enzymes, (3HSDII) which influence hormone production, that low doses of Provera could disrupt GnRH production and high doses were needed for a therapeutic effect. By knowing all this, it brings about new ideas for drug therapy when dealing with certain diseases. Not only that, but 3HSDII enzyme may be great to treat breast cancer. In this study Lee and Auchus used yeast cells instead of human cells. This allows them to study a single enzyme along with the effects that drugs may have on the production of steroids. Another advantage in using yeast cells is that these cells allow the maximum amount of an enzyme, cholesterol and protein needed, in order for the enzyme to perform. I believe that Lee and Auchus expected these results based on their find
All papers and essays are for research and reference purposes only!
Copyright 2002-2009
Direct Essays , LLC. All Rights Reserved. DMCA Webmasters make $$$$